PLRZ - Polyrizon Ltd.


13.46
0.260   1.932%

Share volume: 31,543
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.72%

PREVIOUS CLOSE
CHG
CHG%

$13.20
0.26
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
7.65%
1 Month
8.29%
3 Months
2.75%
6 Months
1,219.61%
1 Year
1,647.14%
2 Year
1,194.23%
Key data
Stock price
$13.46
P/E Ratio 
N/A
DAY RANGE
$13.00 - $13.50
EPS 
N/A
52 WEEK RANGE
$0.00 - $18.20
52 WEEK CHANGE
$1,536.28
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.41
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$41,030
AVERAGE 30 VOLUME 
$56,345
Company detail
CEO: Tomer Izraeli
Region: US
Website: polyrizon-biotech.com
Employees: 0
IPO year: 2024
Issue type:
Market: NASDAQ
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. We are an Israeli corporation, incorporated in January 2005. Our principal executive offices are located at 5 Ha-Tidhar Street, Raanana, 4366507, Israel.

Recent news